(Q40862193)

24 September 2017

Activating ERBB4 mutations in non-small cell lung cancer (English)

1 reference

24 September 2017

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26050618%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

Klaus Elenius

series ordinal

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26050618%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

author name string

K Denessiouk

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26050618%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

M S Johnson

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26050618%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

language of work or name

English

0 references

publication date

8 June 2015

1 reference

24 September 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26050618%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

volume

35

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26050618%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26050618%20AND%20SRC:MED&resulttype=core&format=json

13 June 2020

page(s)

1283-1291

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26050618%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/onc.2015.185

13 June 2020

exact match

0 references

cites work

Global cancer statistics

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.185

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.185

Management of non-small-cell lung cancer: recent developments

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.185

Somatic mutations affect key pathways in lung adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.185

Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.185

Comprehensive genomic characterization of squamous cell lung cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.185

Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.185

A landscape of driver mutations in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.185

Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.185

Somatic mutations of ErbB4: selective loss-of-function phenotype affecting signal transduction pathways in cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.185

Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.185

The extracellular region of ErbB4 adopts a tethered conformation in the absence of ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.185

A single ligand is sufficient to activate EGFR dimers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.185

ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.185

A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.185

Structural Basis for Negative Cooperativity in Growth Factor Binding to an EGF Receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.185

Novel vascular endothelial growth factor D variants with increased biological activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.185

Mechanism of activation and inhibition of the HER4/ErbB4 kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.185

An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.185

Her4 and Her2/neu tyrosine kinase domains dimerize and activate in a reconstituted in vitro system

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.185

Mechanism for activation of mutated epidermal growth factor receptors in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.185

gamma -Secretase cleavage and nuclear localization of ErbB-4 receptor tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.185

Presenilin-dependent gamma-secretase-like intramembrane cleavage of ErbB4.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.185

WW domain-containing protein YAP associates with ErbB-4 and acts as a co-transcriptional activator for the carboxyl-terminal fragment of ErbB-4 that translocates to the nucleus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.185

The ERBB4/HER4 receptor tyrosine kinase regulates gene expression by functioning as a STAT5A nuclear chaperone

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.185

Proteolytic cleavage and phosphorylation of a tumor-associated ErbB4 isoform promote ligand-independent survival and cancer cell growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.185

Presenilin-dependent ErbB4 nuclear signaling regulates the timing of astrogenesis in the developing brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.185

Cell death or survival promoted by alternative isoforms of ErbB4

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.185

Oncogenic ERBB3 mutations in human cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.185

Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.185

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.185

Epidermal growth factor receptor mutations in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.185

Blocking NRG1 and other ligand-mediated Her4 signaling enhances the magnitude and duration of the chemotherapeutic response of non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.185

ERBB4 mutations that disrupt the neuregulin-ErbB4 pathway cause amyotrophic lateral sclerosis type 19

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.185

Structural Analysis of the Mechanism of Inhibition and Allosteric Activation of the Kinase Domain of HER2 Protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.185

BODIL: a molecular modeling environment for structure-function analysis and drug design.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.185

Cleavable ErbB4 isoform in estrogen receptor-regulated growth of breast cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.185

Mutated ERBB4: a novel drug target in metastatic melanoma?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.185

A therapeutic opportunity in melanoma: ErbB4 makes a mark on skin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FONC.2015.185

Identification of patients with transitional cell carcinoma of the bladder overexpressing ErbB2, ErbB3, or specific ErbB4 isoforms: real-time reverse transcription-PCR analysis in estimation of ErbB receptor status from cancer patients.

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26050618